Cargando…

Acute Myeloid Leukemia as a Model for Cancer Therapy

Detalles Bibliográficos
Autor principal:	Ravandi, Farhad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469793/ https://www.ncbi.nlm.nih.gov/pubmed/23091801 http://dx.doi.org/10.3389/fonc.2012.00139

Ejemplares similares

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

Editorial: Acute Promyelocytic Leukemia — Towards A Chemotherapy-Free Approach to Cure in All Patients
por: Gill, Harinder, et al.
Publicado: (2022)

Murine Models of Acute Myeloid Leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2022)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

Corrigendum: Murine models of acute myeloid leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2023)

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
por: Nazha, Aziz, et al.
Publicado: (2013)

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
por: Short, Nicholas J., et al.
Publicado: (2019)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
por: Dembitz, Vilma, et al.
Publicado: (2021)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia
por: Manobianco, Steven A., et al.
Publicado: (2022)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Therapeutic targeting of leukemia stem cells in acute myeloid leukemia
por: Barbosa, Karina, et al.
Publicado: (2023)

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2021)

The research progress of targeted therapy in acute myeloid leukemia based on bibliometric analysis
por: Huang, Wanxue, et al.
Publicado: (2022)

Genomics of Acute Myeloid Leukemia: The Next Generation
por: Riva, Laura, et al.
Publicado: (2012)

Clinical Implications of Inflammation in Acute Myeloid Leukemia
por: Récher, Christian
Publicado: (2021)

Editorial: Precision medicine for acute myeloid leukemia
por: Marconi, Giovanni, et al.
Publicado: (2023)

Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Debating Frontline Therapy in Chronic Myeloid Leukemia
por: Bi, Xia, et al.
Publicado: (2021)

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
por: Pettit, Kristen, et al.
Publicado: (2015)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia
por: Horvat, Nathan P, et al.
Publicado: (2022)

Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients
por: Gill, Navroop, et al.
Publicado: (2020)

Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia
por: Pulikkan, John Anto, et al.
Publicado: (2018)

Harnessing the Metabolic Vulnerabilities of Leukemia Stem Cells to Eradicate Acute Myeloid Leukemia
por: Kumar, Bijender
Publicado: (2021)

Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia
por: Tasian, Sarah K., et al.
Publicado: (2014)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2019)

Vitamin C Deficiency in Patients With Acute Myeloid Leukemia
por: Ottone, Tiziana, et al.
Publicado: (2022)

Research progress on molecular biomarkers of acute myeloid leukemia
por: Yin, Pei-Yuan, et al.
Publicado: (2023)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective
por: Chang, Ying-Jun, et al.
Publicado: (2021)

Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_74l584anum0mleaofqp0vn5r3a